Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration

Published: Monday, July 30, 2012
Last Updated: Monday, July 30, 2012
Bookmark and Share
Third Stargardt's patient in EU trial treated with RPE cells derived from human embryonic Stem Cells at Moorfields Eye Hospital in London.

Advanced Cell Technology, Inc. announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, July 27 at Moorfields Eye Hospital in London, the same site as the first two treatments, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The outpatient transplant surgery was performed successfully without any complications, and the patient is recovering uneventfully. This is the tenth patient overall to now be treated with the RPE cell therapy developed by the company.

"Our European trial is making very steady progress, having now completed enrollment of the first patient cohort," commented Gary Rabin, chairman and CEO. "We are very encouraged and look forward to receiving clearance to initiate the treatment of the second patient cohort in the coming weeks."

The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.

"This is a significant month for the company," continued Mr. Rabin. "One year ago we treated the first of our patients in our two U.S. clinical trials. The one-year follow-up for those initial patients indicates that the improvements in visual acuity we initially reported have in fact persisted now for a year. Indeed, we are consistently observing improvements in subjective and objective visual acuity for patients being treated at the various clinical centers involved in our trials. Again, these trials are still at very early stages, but these preliminary results indicate that we are on the right track."

The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of SMD.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Positive Safety Results for Macular Degeneration Treatment
Phase 1/2 clinical trials of RPE cells for the treatment of dry age-related macular degeneration and Stargardt’s macular degeneration show positive long term safety results and signs of visual improvement.
Thursday, October 16, 2014
ACT Issued Broad Patent for Human RPE Cells
New Australian patent covers human RPE cells made from range of pluripotent stem cells, including both embryonic stem cells and iPS cells.
Tuesday, July 31, 2012
Stargardt Patient Treated With Retinal Pigment Epithelial Cells
Patient injected with 100,000 RPE cells at Wills Eye Institute.
Friday, July 13, 2012
ACT Announces Europe's First Human Embryonic Stem Cell Transplant in Patient with Stargardt's Disease
Moorfields Eye Hospital in London initiates clinical trial using hESC-derived RPE cells.
Monday, January 23, 2012
Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial
Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells.
Tuesday, January 17, 2012
Advanced Cell Technology's CEO Says Markets Are Just Starting to Appreciate the Significance of Their Stem Cell Derived Treatments
Several key announcements have pushed Advanced Cell Technology's stock from just under a nickel in late November to an intraday high of $.20 during Wednesday's session and volume has made it apparent that a growing crowd of day traders momentum players have now joined biotech investors in cheering on the small biotech.
Friday, December 10, 2010
ACT Receives FDA Clearance for the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
Company to commence a Phase I/II clinical trial at multiple centers.
Wednesday, November 24, 2010
NIH Approves Advanced Cell Technology’s Stem Cell Line for Federal Funding
Access to federal funding could accelerate clinical development.
Monday, June 14, 2010
ACT Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease
The Phase I/II trial will be an open-label study designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation.
Thursday, November 26, 2009
Embryonic Stem Cells to Treat Eye Disease - ACTC Advanced Cell Technology Files IND with FDA
Advanced Cell Technology files IND with FDA for first human clinical trial using embryonic stem cells to treat eye disease.
Monday, November 23, 2009
Functional Vasculature Generated from Advanced Cell Technology’s Human Embryonic Stem Cells
Hemangioblasts form multilayered blood vessels with functional smooth muscle; could provide an inexhaustible source of cells to treat vascular disease.
Tuesday, January 06, 2009
Advanced Cell Technology and CHA Biotech Form new International Stem Cell Company
The new company; Allied Cell Technology; will develop human blood cells and other clinical therapies based on ACTC’s hemangioblast cell technology.
Tuesday, December 02, 2008
Clinical-Scale Generation of Functional Red Blood Cells from Human Embryonic Stem Cells
ACT reports that it is feasible to differentiate and mature hESCs into functional oxygen-carrying RBCs under conditions suitable for scale-up.
Wednesday, August 20, 2008
Advanced Cell Technology Demonstrates Generation of Functional Hepatocytes from Human Embryonic Stem Cells
The research signifies a step towards the efficient generation of hepatocytes for use in regenerative medicine and drug discovery.
Friday, February 22, 2008
Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines without the Destruction of Embryos
Breakthrough approach improves efficiency to levels reported in the conventional stem cell derivation techniques.
Friday, January 11, 2008
Scientific News
Crucial for Stem Cell Survival Protein Identified Using Editing Tool CRISPR
A team of University of Wisconsin-Madison engineers has identified a protein that is integral to the survival and self-renewal processes of human pluripotent stem cells (hPSC).
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!